Celiac disease (CD) is a chronic infl ammatory disease of the small bowel that is characterized by increased intraepithelial lymphocytes (IELs) and villous atrophy of the mucosa. It is unclear how often intraepithelial lymphocytosis in the absence of atrophy is a manifestation of gluten sensitive enteropathy. The objective of this study was to identify factors that discriminate patients with CD from those with lymphocytic duodenosis (LD, intraepithelial lymphocytosis without villous atrophy). We compared Class 2 HLA type, presenting symptoms, and serology in patients with LD and CD.
INTRODUCTION
Celiac disease (CD) is a chronic in ammatory disease of the small bowel that occurs with the ingestion of gluten, which can be found in grain products such as wheat, barley, and rye (1) . Upon ingestion of gluten, people with CD mount a T-cell-mediated reaction, which can lead to the characteristic mucosal lesions of intraepithelial lymphocytosis and villous atrophy (2 -4) . Patients can present with symptoms of malabsorption, such as diarrhea, steatorrhea, weight loss, and nutrient and mineral de ciencies (3) .
Studies have shown there is a genetic component that is crucial to the etiology of CD. For example, people with the gene pair encoding the major histocompatibility complex Class 2 HLA DQ2, may be more susceptible to CD (5, 6) . Indeed, it has been shown that not only there is an association with CD but that DQ2 or occasionally DQ8 HLA genes are virtually Lymphocytic Duodenosis and the Spectrum of Celiac Disease required for CD to occur. e absence of these genes makes CD very unlikely. By evaluating HLA type, we may gain insight into whether someone is more or less likely of having a diagnosis of CD when the initial evaluation of duodenal biopsy neither identi es nor rules out the diagnosis of CD (7, 8) . Such a circumstance occurs when the duodenal biopsy reveals an increase in intraepithelial lymphocytes (IELs) but lacks the villous atrophy and chronic in ammation that characterizes CD. Although serology speci c for CD has been used as an adjunctive test for CD, their utility in those with minor changes suggestive of CD is limited as most such patients are seronegative (9, 10) .
As the awareness of the high frequency of CD increases, more patients undergoing an upper endoscopy are having routine duodenal biopsies taken. Although CD may be the most common explanation for biopsies showing villous atrophy with in ammation in the Western populations, lymphocytic duodenosis (LD) is becoming a more frequent pathological nding. LD can also be associated with autoimmune disorders, food protein intolerance, Helicobacter pylori gastritis, parasitic infections, or nonsteroidal antiin ammatory drugs use (11, 12) . It is not clear what this means clinically and how many patients with this pathological nding belong to the spectrum of gluten-sensitive enteropathy. e aim of this study is to report a systematic evaluation of patients who are found to have LD through biopsies obtained clinically and to compare their HLA typing, celiac serology, and clinical features with patients with established CD.
METHODS
is retrospective study of 124 patients who had duodenal biopsies with increased IELs (de ned as >40 IEL per 100 epithelial nuclei) and normal villous architecture, referred to as LD, were systematically evaluated at the Mayo Clinic from July 1997 to November 2006 (13) . ese patients were then compared to 454 patients who had a diagnosis of CD based on duodenal biopsies with >40 IELs per 100 enterocytes and villous atrophy without other explanation for these changes evaluated during the same time period (7) . As a routine four duodenal biopsies were obtained from each patient at index endoscopy. Only patients (total of 578) that had Class 2 HLA typing performed were included. Only one individual per pedigree was used so as to not overpopulate the sample with a single family having similar genes.
e clinical records of all patients in this study were reviewed for the following: age, gender and race, date of diagnosis, residency at time of diagnosis, and presenting symptoms (presence or absence of the following: diarrhea, greasy stool, abdominal distention, abdominal cramping, atulence, ascites, edema, anorexia, weight loss, nausea / vomiting, paresthesia, tetany, bone pain, anemia, malaise, skin disorder, in amed mouth (canker sores, mouth ulcers), itchy skin, headaches, family history of CD, failure to thrive (persistently below third percentile for weight or < 80 % ideal body weight), poor increase in height (height < 3rd percentile for age), and constipation).
Most of the subjects had serological testing undertaken at Mayo Medical Laboratories. However, a small proportion had these tests performed in other labs. Serology testing (endomysial antibody, EMA, TTg (immunoglobulin A, IgA), TTg (IgG), gliadin IgA, gliadin IgG) was reported only if it was completed close to the time of the intestinal biopsy and while the patient was on a normal gluten-containing diet. If the patient had been on a gluten-free diet (GFD) subsequent to the biopsy, the response to a GFD (either an objective or subjective response) was recorded. Note that only patients who were on a normal gluten-containing diet at the time of the biopsy were included in the study.
e clinical records were abstracted independently by two people (an experienced study coordinator and the primary investigator) to help ensure accuracy.
All patients in the study were seen at the Mayo Clinic and were individuals who sought medical evaluation for clinically signi cant symptoms. Participants were identi ed from the Medical Diagnostic Index, Celiac Disease Clinic, and Mayo Clinic Life Sciences System. e majority of the patients were seen in the Division of Gastroenterology and Hepatology. All patients with CD were recruited for a separate study on Epidemiology of Celiac Disease or had HLA performed as part of their clinical care.
HLA genotyping
Low-resolution HLA Class 2 gene typing, including both the DR and DQ alleles, was completed on all patients in the study. Some patients also underwent high-resolution typing. DNA was extracted from peripheral blood for HLA typing of DR and DQ alleles. Typing methodology was PCR with sequencespeci c primers (PCR-SSP), low resolution (One Lambda, Canoga Park, CA) and high resolution (Genovision, West Chester, PA) (14) .
Although high-resolution typing was not performed on all subjects, we were able to extrapolate the DR typing in combination to infer the DQA1 alleles carried. We found this was highly accurate based on 285 subjects who had both high-and low-resolution typing. Subjects were considered to carry the CD susceptibility genotype only if there was carriage of both of the relevant DQA and DQB alleles.
Serology
Tissue transglutaminase IgA was determined from the enzymelinked immunosorbent assay procedure, which is performed with a commercially available enzyme-linked immunosorbent assay kit using human TTg antigen ( e Binding Site, Birmingham UK). e calibrators, controls, and diluted patient samples are added to the wells and autoantibodies recognizing the TTg antigen bound during the rst incubation. e results were classi ed as negative, weakly positive, or strongly positive.
Endomysial antibodies of the IgA subclass present in the serum bind to the reticulin component of the endomysium of the smooth muscle in monkey esophagus tissue (15) detected by indirect immuno uorescence. In brief, diluted (1:5 and 1:20) serum samples were incubated with air-dried 5 m cryostat sections of monkey esophagus ( e Binding Site) for 30 min at room temperature. Subsequently, unbound antibody is rinsed free and excess bu er removed by blotting. Substratebound IgA antibody is then identi ed with a uorescent antihuman IgA (Fab2-speci c) conjugate ( e Binding Site), and the staining pattern examined with a Zeiss microscope with Zeiss IV FL vertical illumination for epi uorescence and a uorescein lter system (Carl Zeiss, ornwood, NY). A positive cuto of 1:5 was selected as normal sera at lower dilutions produced nonspeci c substrate staining. Positive staining is identi ed as a reticulated lace-like pattern surrounding smooth muscle bundles at dilutions of 1:5 and 1:20.
Gliadin testing was performed by enzyme-linked immunosorbent assay using both IgA and IgG isotype using a commercial kit from Scimedix.
e patients ' serology testing was only included in this study if it was completed close to the time of the intestinal biopsy and while the patient was still on a normal gluten-containing diet.
Statistical analysis
Descriptive statistics were rst used to summarize the data on all subjects, strati ed by speci c type of disease LD or CD. Categorical parameters were expressed by the number and percentage among the nonmissing total, and continuous parameters were represented by the mean and standard deviation. Di erences in continuous parameters between the two disease-speci c groups were tested using a t -test, whereas associations between categorical variables and group were assessed using the standard two-way contingency table method along with a 2 -test or Fisher ' s exact test. Logistic regression was employed to further distinguish between the LD and CD groups, such that prognostic factors associated with higher risk of LD relative to CD (or vice versa) could be identi ed. A univariate logistic model postulates a relationship between the log odds of response (LD vs. CD) and the prognostic factor under investigation. Odds ratios (ORs) were presented to convey the strength of association and quantify the risk of developing one disease vs. the other as a function of the corresponding factor. An additional utility of logistic modeling, estimates of e ect can be produced while controlling for other covariates that otherwise may confound the response -risk factor relationship. Using multivariate regression adjustment for the factors age and gender, additional ORs were obtained to determine associations independent of those two regular confounders. A signi cance level of = 0.05 was used for all analyses.
RESULTS

Demographic information
ere was no statistical di erence in gender or age distributions between the LD and CD cohorts. Although there was a signi cantly lower proportion of declared Caucasians in the LD group, this was due to a greater number of individuals who did not declare their race and ethnicity. Also, a higher majority of patients in the LD cohort were residents of locations other than the southeastern part of Minnesota at the time of diagnosis ( Table 1 ) .
Clinical symptoms e majority (65 % ) of LD patients presented with chronic diarrhea. Furthermore, 43 % had abdominal cramping, 37 % had weight loss, 33 % had abdominal distention, 33 % had nausea / vomiting, and 25 % presented with constipation. When compared to those individuals with villous atrophy, LD patients were signi cantly less likely to have anemia, malaise, or skin disorders a er adjusting for age and gender. In contrast, LD patients were signi cantly or marginally more likely than CD patients to have diarrhea and nausea / vomiting, again a er controlling for age and gender e ects ( Table 2 ) .
HLA genotype
Most patients with LD lack the HLA types associated with CD. When comparing the rates of allele presence (either one or both alleles) between patients with LD histology and those with CD, DQ2 is signi cantly less prevalent in the LD group (37 % vs. 91 % , P < 0.001). DQ8 rates are not signi cantly di erent in the two groups. When compared to the CD cohort, there is a marginally higher proportion of LD patients that have the DQ8 allele without having the DQ2 allele (12 % vs. 7 % , OR = 1.96, P = 0.045), and a signi cantly higher proportion without either DQ2 or DQ8 (51 % vs. 2 % , OR = 44.5, P < 0.001) ( Table 3 ). e pro le of patients with CD who did not have either DQ2 or DQ8 is shown in Table 4 . 
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Serology at the time of diagnosis
A total of 93 % of the tested CD patients had tested positive for either EMA, TTg, or gliadin, whereas only 27 % in the LD cohort tested had some type of serology positivity ( P < 0.001) ( Table 5 ). Of the 313 seropositive CD patients, 308 of those were DQ2 / 8 positive. Of the 31 seropositive LD patients, 17 of those were DQ2 / 8 positive. e 14 patients with LD who lacked both DQ2 and DQ8 were positive for gliadin antibodies alone or their level of TTg -IgA was close to the negative threshold. Just 10.8 % ( n = 12) of the LD patients tested were positive EMA or TTg whereas 90.5 % ( n = 284) of the CD patients tested positive ( P < 0.0001).
Family history
Of the 124 patients with LD, only 10 (8 % ) had a family history of CD, compared to 97 of 454 (21 % ) CD patients with a family history ( P < 0.001). Of the 10 LD patients with a family nding. e main observation of this systematic study is that patients with LD are substantially di erent as a group from those with CD. When taken as a group, one-half lacks the HLA gene pairs thought to impart susceptibility for CD, and they are much less likely to test positive serologically with any of the tests used to detect for CD. Furthermore, they o en lack the objective features speci c for malabsorption such as anemia and weight loss. e high rate of diarrhea in this population is likely the result of a selection bias of those who underwent biopsies.
Although the majority of patients with LD di er from those patients with CD, there is a subgroup of LD patients who have features supportive of gluten sensitivity. For example, of the 124 LD patients, there were 46 (37 % ) who carried the DQ2 alleles. Furthermore, although only 114 out of 124 LD patients had serology tests at the time of biopsies, 12 (10.8 % ) did have a positive result for EMA or TTg antibody. is attests to the fact that within the population of patients with LD and symptoms, a subpopulation of these are part of the spectrum of glutensensitive enteropathy and would likely bene t from being treated as such. ose patients who were negative for TTG or EMA antibodies even if they had gliadin antibodies, form a third indeterminate group who carry the at-risk genotype and for whom gluten sensitivity remains a possibility but is less certain.
Of our cohort of LD patients, almost two-thirds had neither the DQ2 allele nor the serological evidence for CD suggesting that the majority of LD patients, do not belong on the spectrum of CD. It is likely that LD represents a common in ammatory response of the epithelium to a number of noxious or in ammatory signals. is lymphocytosis could represent a nonspeci c, innate response to many luminal noxious factors including bacteria or to in ammatory markers such as H . pylori , Crohn ' s disease, or other autoimmune disorders. It is also possible that even certain gluten peptides that are not those involved in the DQ-restricted T-cell-mediated adaptive response characteristic of CD, may trigger a response in the surface epithelium (11, 12) .
is study is based on a population of patients who sought medical evaluation for clinically signi cant symptoms and may history of CD, only 1 person had neither a DQ2 nor a DQ8 allele. Among the 97 CD patients with a family history, only two people had neither a DQ2 nor a DQ8 allele ( Table 6 ).
Response to a gluten-free diet
Of the 124 LD patients, 36 of them had a documented trial of a GFD with either a positive or negative response that was recorded at follow-up. A total of 29 of those individuals responded to the diet, whereas 7 did not show any improvement. Of those 29 responders, 14 people had an objective response that included correction of anemia ( n = 1), reversion of serology from positive to negative ( n = 5), improvement in biopsy ( n = 3), reversion of serology and improved biopsy ( n = 4), and reversion of serology with improved biopsy and correction of anemia ( n = 1). Although all 454 CD patients were advised to follow a GFD, 352 had a documented response to the GFD at follow-up. Of these individuals, 345 had a positive response whereas 7 people had no response. ose who lacked any symptoms at diagnosis or at least a documented follow-up 3 or more months a er institution of the GFD were excluded.
Each individual was then assessed for whether they carried at least one pair of the genes encoding the DQ2 or DQ8 serotypes equivalents ( Table 7 ) .
Other diagnoses
While testing for other possible explanations for LD was not as systematic, 64 subjects had gastric biopsies performed at the time of the index endoscopy, of whom 4 were H. pylori positive. Of 49 subjects tested, 5 had small intestinal bacterial overgrowth based on duodenal aspirates taken at the same time. Other disorders such as microscopic colitis and IBD a ected a handful of patients only. In most LD patients with diarrhea, it was assumed that the cause was idiopathic (31.3 % ), functional, or irritable bowel syndrome (IBS) (27.5 % ) or medication induced (8.8 % ) .
DISCUSSION
Along with the increased awareness of CD as a diagnostic consideration has come a much greater number of duodenal biopsies that require pathological interpretation. e nding of isolated LD is becoming an increasingly common histological Another situation where these conclusions may not apply are in those patients with dermatitis herpetiformis wherein even the mild degrees of enteropathy are highly likely to be a manifestation of gluten sensitivity (16, 17) . is observational study is limited by not having a randomized therapeutic protocol. A future therapeutic study is needed to determine if and indeed, which symptomatic LD patients will respond to a GFD. How do our results intersect with the classi cation of CD? ere have been several studies supporting the role of gluten in patients with, LD, or even just electron microscopic changes of the surface of the enterocytes that improve along with symptoms on a GFD (18) . is appears to occur in the context of the CD-associated HLA type. In some of these studies the patients have positive serological tests for CD and in others the celiacspeci c serology is negative (19, 20) . Our study suggests that LD segregates into two distinct groups. ose patients with LD who are seropositive and carry the CD susceptibility genes, belong to the spectrum of gluten-sensitive enteropathy whereas the majority, who lack genetic and serological evidence of CD, do not. A minority of subjects remain for whom gluten sensitivity remains a possible explanation for the minimal histological change and potential symptoms.
Interestingly, of the 25 LD patients who responded to a GFD, 11 of them did not carry the HLA types associated with CD.
e subjective response to a GFD reported by those LD patients who lack DQ2 or DQ8 may be a response to a general reduction in carbohydrate ingestion. However, we cannot discount the possibility that other (non-HLA associated) responses to gluten can occur (21) . Possibly, this may suggest that there are other immune reactions to gluten beyond the standard HLArestricted types. ere may be symptomatic consequences of these innate responses to gluten or other components of cereals (22) . ere are reports in the literature that patients with d-IBS may also respond to gluten avoidance, especially in those who are also serum IgG and DQ2 positive (11, 19) . Indeed, the combination of LD with the at-risk HLA type suggests that these patients truly belong somewhere on the spectrum of gluten-sensitive enteropathy, even though most patients with LD do not belong in that spectrum. Although gluten-sensitive enteropathy may explain some cases of LD, there are likely other explanations involved that are yet to be explored.
In summary, LD is an increasingly recognized pathological nding, and our study provides evidence that HLA genotype, celiac serology, and clinical symptoms such as anemia, malaise, or skin disorders can be used to dissect a well-de ned minority belonging to the spectrum of gluten-sensitive enteropathy from the majority that do not.
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